A drug wholesaler must submit its claims that Johnson & Johnson is illegally suppressing competition for its rheumatoid arthritis treatment Remicade to an arbitrator, a federal appeals court held on Friday.
The 3rd U.S. Circuit Court of Appeals overturned a 2018 ruling that allowed Rochester Drug Cooperative Inc to pursue its antitrust claims in federal court in Philadelphia. The lawsuit alleges that J&J and its Janssen Pharmaceuticals unit have kept the price for Remicade artificially high by coercing insurance companies to deny coverage for less expensive biosimilar versions.
To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2knWDY2